Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening.
Their 22,000 employees come to work every day with a common purpose: to develop and deliver breakthrough therapies that enable people with life-altering conditions to live their lives to the fullest.
At Shire, they are dedicated to expanding, building and sustaining leadership across their key therapeutic areas through their extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. They strive to earn and keep the trust of their patients, their families and physicians, and all others who support and advance their care.
Working together, the possibilities for their patients, healthcare partners and employees are unprecedented, with significant growth potential for their shareholders.